SEMA3A and ovarian carcinoma: Other findings have suggested that decreased Sema3A expression may be associated with the development of epithelial ovarian carcinoma, and therefore, Sema3A may be a valuable prognostic marker and a potential molecular therapy target for ovarian cancer patients [38].